title: Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sézary syndrome.
abstract: Immunodeficiency-related lymphoproliferative disorders (IR-LPD) may occur in the setting of immunosuppressive therapy with methotrexate and TNF-α antagonists. As far as we are aware, this is the first report of an Epstein-Barr virus-associated B-cell lymphoproliferative disorder, secondary to methotrexate therapy in a patient with mycosis fungoides/Sézary syndrome.
authors.affiliation: Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. jlcurry@mdanderson.org
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Curry
authors.forename: Victor G
authors.initials: VG
authors.lastname: Prieto
authors.forename: Dan M
authors.initials: DM
authors.lastname: Jones
authors.forename: Franscisco
authors.initials: F
authors.lastname: Vega
authors.forename: Madeleine
authors.initials: M
authors.lastname: Duvic
authors.forename: A Hafeez
authors.initials: AH
authors.lastname: Diwan
mesh_terms: D000368:Aged; D001379:Azathioprine / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000473:pathology; D020031:Epstein-Barr Virus Infections / Q000150:complications; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008232:Lymphoproliferative Disorders / Q000150:complications / Q000276:immunology* / Q000821:virology; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D009182:Mycosis Fungoides / Q000150:complications* / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use; D012751:Sezary Syndrome / Q000150:complications* / Q000188:drug therapy; D012878:Skin Neoplasms / Q000150:complications* / Q000188:drug therapy
chemical_list: D007166:Immunosuppressive Agents; D001379:Azathioprine; D011241:Prednisone; D008727:Methotrexate